

NA Throat Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 213 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

North America throat cancer diagnostics market is projected to register a substantial CAGR of 7.8% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

North America Throat Cancer Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, and Others), Cancer Type (Pharyngeal Cancer and Laryngeal Cancer), Stages (Stage 0, Stage I, Stage II, Stage III and Stage IV), Age Group (30-65, 65 and above, 21-29 and Below 21), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes and Others) and By Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, and Mexico), Industry Trends and Forecast to 2030

- Rising preference for preventive health check-ups
- Rising healthcare expenditure

Market Players:

Some of the key market players in North America throat cancer diagnostics market are listed below:

- F. Hoffmann-La Roche Ltd.
- FUJIFILM Corporation
- Thermo Fisher Scientific Inc.
- CANON MEDICAL SYSTEMS CORPORATION
- Koninklijke Philips N.V.
- Merck KGaA
- BD
- General Electric Company
- Illumina
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.

Scotts International, EU Vat number: PL 6772247784

- Abbott
- QIAGEN
- Siemens Healthcare GmbH
- Myriad Genetics Inc.
- Quest Diagnostics Incorporated
- Hologic
- FONAR Corp.
- Time Medical Holding.
- MinFound Medical Systems Co., Ltd
- PlexBio.

Table of Contents:

TABLE OF CONTENTS

- 1 INTRODUCTION 46
- 1.1 OBJECTIVES OF THE STUDY 46
- 1.2 MARKET DEFINITION 46
- 1.3 OVERVIEW OF THE NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET 46
- 1.4 LIMITATIONS 48
- 1.5 MARKETS COVERED 48
- 2 MARKET SEGMENTATION 51
- 2.1 MARKETS COVERED 51
- 2.2 GEOGRAPHICAL SCOPE 52
- 2.3 YEARS CONSIDERED FOR THE STUDY 53
- 2.4 CURRENCY AND PRICING 53
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
- 2.6 MULTIVARIATE MODELLING 57
- 2.7 PRODUCT TYPE LIFELINE CURVE 57
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
- 2.9 DBMR MARKET POSITION GRID 59
- 2.10 MARKET END USER COVERAGE GRID 60
- 2.11 VENDOR SHARE ANALYSIS 61
- 2.12 SECONDARY SOURCES 62
- 2.13 ASSUMPTIONS 62
- 3 EXECUTIVE SUMMARY 63
- 4 PREMIUM INSIGHTS 66
- 4.1 PESTEL ANALYSIS 67
- 4.2 PORTER'S FIVE FORCES 68
- 5 INDUSTRY INSIGHTS 69
- 6 EPIDEMIOLOGY 70
- 7 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, REGULATIONS 71
- 7.1 REGULATORY SCENARIO IN THE U.S 71
- 7.2 REGULATORY SCENARIO IN AUSTRALIA 72
- 7.3 REGULATORY SCENARIO IN JAPAN 72
- 7.4 REGULATORY SCENARIO IN CHINA 72
- 8 MARKET OVERVIEW 74

Scotts International. EU Vat number: PL 6772247784

- **8.1 DRIVERS 76**
- 8.1.1 GROWING PREVALENCE OF THROAT CANCER 76
- 8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN THROAT CANCER DIAGNOSTICS 76
- 8.1.3 INCREASE IN AWARENESS REGARDING THROAT CANCER 77
- 8.2 RESTRAINTS 77
- 8.2.1 LATE DIAGNOSIS AND POOR PROGNOSIS OF THROAT CANCER 77
- 8.2.2 HIGH COST FOR THE INSTALLATION OF DIAGNOSTIC DEVICES. 77
- 8.3 OPPORTUNITIES 78
- 8.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 78
- 8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 79
- 8.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 79
- 8.4 CHALLENGES 80
- 8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 80
- 8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 80
- 9 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 81
- 9.1 OVERVIEW 82
- 9.2 INSTRUMENTS 85
- 9.2.1 PATHOLOGY-BASED INSTRUMENTS 86
- 9.2.1.1 PCR INSTRUMENTS 86
- 9.2.1.2 SLIDE STAINING SYSTEMS 86
- 9.2.1.3 TISSUE PROCESSING SYSTEMS 87
- 9.2.1.4 CELL PROCESSORS 87
- 9.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 87
- 9.2.2 IMAGING INSTRUMENTS 87
- 9.2.2.1 ULTRASOUND SYSTEMS 87
- 9.2.2.2 CT SYSTEMS 87
- 9.2.2.3 MRI SYSTEMS 87
- 9.2.2.4 OTHERS 88
- 9.2.3 BIOPSY INSTRUMENTS 88
- 9.2.4 OTHERS 88
- 9.3 CONSUMABLES & ACCESSORIES 88
- 9.3.1 KITS 89
- 9.3.1.1 PCR KITS 89
- 9.3.1.2 DNA POLYMERASE KITS 89
- 9.3.1.3 NUCLEIC ACID ISOLATION KITS 89
- 9.3.1.4 OTHERS 90
- 9.3.2 REAGENTS 90
- 9.3.2.1 ASSAYS 90
- 9.3.2.2 BUFFERS 90
- 9.3.2.3 PRIMERS 90
- 9.3.2.4 OTHERS 90
- 9.3.3 PROBES 90
- 9.3.4 OTHER CONSUMABLES 90
- 10 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY TEST TYPE 91
- **10.1 OVERVIEW 92**
- 10.2 IMAGING TEST 95
- 10.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 96

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.2 MRI 96
- 10.2.3 CHEST X-RAY 96
- 10.2.4 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 96
- 10.2.5 OTHERS 96
- 10.3 BLOOD TEST 96
- 10.3.1 BLOOD CHEMISTRY TESTS 98
- 10.3.2 COMPLETE BLOOD COUNT (CBC) 98
- 10.3.3 OTHERS 98
- 10.4 BIOPSY 98
- 10.4.1 ENDOSCOPIC BIOPSY 99
- 10.4.2 FINE NEEDLE ASPIRATION (FNA) BIOPSY 99
- 10.4.3 OTHERS 99
- 10.5 OTHERS 100
- 11 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 101
- 11.1 OVERVIEW 102
- 11.2 PHARYNGEAL CANCER 105
- 11.2.1 NASOPHARYNGEAL CANCER 106
- 11.2.2 OROPHARYNGEAL CANCER 106
- 11.2.3 HYPOPHARYNGEAL CANCER 106
- 11.3 LARYNGEAL CANCER 107
- 12 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY STAGES 108
- 12.1 OVERVIEW 109
- 12.2 STAGE III 112
- 12.3 STAGE II 112
- 12.4 STAGE IV 113
- 12.5 STAGE I 114
- 12.6 STAGE 0 115
- 13 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY AGE 116
- 13.1 OVERVIEW 117
- 13.2 30-65 120
- 13.3 65 AND ABOVE 121
- 13.4 21-29 121
- 13.5 BELOW 21 122
- 14 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY END USER 123
- 14.1 OVERVIEW 124
- **14.2 HOSPITALS 127**
- 14.3 ASSOCIATED LABS 127
- 14.4 INDEPENDENT DIAGNOSTIC LABORATORIES 128
- 14.5 DIAGNOSTIC IMAGING CENTERS 129
- 14.6 CANCER RESEARCH INSTITUTES 130
- 14.7 OTHERS 131
- 15 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 132
- 15.1 OVERVIEW 133
- 15.2 DIRECT TENDER 136
- 15.3 RETAIL SALES 137
- 16 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY REGION 138
- 16.1 NORTH AMERICA 139

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.1 U.S. 149
- 16.1.2 CANADA 154
- 16.1.3 MEXICO 159
- 17 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 164
- 17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 164
- 18 SWOT ANALYSIS 165
- 19 COMPANY PROFILE 166
- 19.1 F. HOFFMANN- LA ROCHE LTD 166
- 19.1.1 COMPANY SNAPSHOT 166
- 19.1.2 REVENUE ANALYSIS 166
- 19.1.3 COMPANY SHARE ANALYSIS 167
- 19.1.4 PRODUCT PORTFOLIO 167
- 19.1.5 RECENT DEVELOPMENT 167
- 19.2 FUIIFILM CORPORATION 168
- 19.2.1 COMPANY SNAPSHOT 168
- 19.2.2 REVENUE ANALYSIS 168
- 19.2.3 COMPANY SHARE ANALYSIS 169
- 19.2.4 PRODUCT PORTFOLIO 169
- 19.2.5 RECENT DEVELOPMENT 169
- 19.3 THERMO FISHER SCIENTIFIC INC. 170
- 19.3.1 COMPANY SNAPSHOT 170
- 19.3.2 REVENUE ANALYSIS 170
- 19.3.3 COMPANY SHARE ANALYSIS 171
- 19.3.4 PRODUCT PORTFOLIO 171
- 19.3.5 RECENT DEVELOPMENTS 171
- 19.4 CANON MEDICAL SYSTEMS CORPORATION 172
- 19.4.1 COMPANY SNAPSHOT 172
- 19.4.2 REVENUE ANALYSIS 172
- 19.4.3 COMPANY SHARE ANALYSIS 173
- 19.4.4 PRODUCT PORTFOLIO 173
- 19.4.5 RECENT DEVELOPMENT 173
- 19.5 KONINKLIJKE PHILIPS N.V. 174
- 19.5.1 COMPANY SNAPSHOT 174
- 19.5.2 REVENUE ANALYSIS 174
- 19.5.3 COMPANY SHARE ANALYSIS 175
- 19.5.4 PRODUCT PORTFOLIO 175
- 19.5.5 RECENT DEVELOPMENT 176
- 19.6 ABBOTT 177
- 19.6.1 COMPANY SNAPSHOT 177
- 19.6.2 REVENUE ANALYSIS 177
- 19.6.3 PRODUCT PORTFOLIO 178
- 19.6.4 RECENT DEVELOPMENTS 178
- 19.7 AGILENT TECHNOLOGIES, INC. 179
- 19.7.1 COMPANY SNAPSHOT 179
- 19.7.2 REVENUE ANALYSIS 179
- 19.7.3 PRODUCT PORTFOLIO 180
- 19.7.4 RECENT DEVELOPMENT 180

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.8 BD 181
- 19.8.1 COMPANY SNAPSHOT 181
- 19.8.2 REVENUE ANALYSIS 181
- 19.8.3 PRODUCT PORTFOLIO 182
- 19.8.4 RECENT DEVELOPMENTS 182
- 19.9 BEIJING O&D BIOTECH CO., LTD. 183
- 19.9.1 COMPANY SNAPSHOT 183
- 19.9.2 PRODUCT PORTFOLIO 183
- 19.9.3 RECENT DEVELOPMENT 183
- 19.10 BIO-RAD LABORATORIES, INC. 184
- 19.10.1 COMPANY SNAPSHOT 184
- 19.10.2 REVENUE ANALYSIS 184
- 19.10.3 PRODUCT PORTFOLIO 185
- 19.10.4 RECENT DEVELOPMENT 185
- 19.11 FONAR CORP. 186
- 19.11.1 COMPANY SNAPSHOT 186
- 19.11.2 REVENUE ANALYSIS 186
- 19.11.3 PRODUCT PORTFOLIO 187
- 19.11.4 RECENT DEVELOPMENT 187
- 19.12 GE HEALTHCARE 188
- 19.12.1 COMPANY SNAPSHOT 188
- 19.12.2 REVENUE ANALYSIS 188
- 19.12.3 PRODUCT PORTFOLIO 189
- 19.12.4 RECENT DEVELOPMENT 189
- 19.13 HOLOGIC INC. 190
- 19.13.1 COMPANY SNAPSHOT 190
- 19.13.2 REVENUE ANALYSIS 190
- 19.13.3 PRODUCT PORTFOLIO 191
- 19.13.4 RECENT DEVELOPMENT 191
- 19.14 ILLUMINA, INC. 192
- 19.14.1 COMPANY SNAPSHOT 192
- 19.14.2 REVENUE ANALYSIS 192
- 19.14.3 PRODUCT PORTFOLIO 193
- 19.14.4 RECENT DEVELOPMENT 193
- 19.15 MEDONICA CO. LTD 194
- 19.15.1 COMPANY SNAPSHOT 194
- 19.15.2 PRODUCT PORTFOLIO 194
- 19.15.3 RECENT DEVELOPMENT 194
- 19.16 MERCK KGAA 195
- 19.16.1 COMPANY SNAPSHOT 195
- 19.16.2 REVENUE ANALYSIS 195
- 19.16.3 PRODUCT PORTFOLIO 196
- 19.16.4 RECENT DEVELOPMENT 196
- 19.17 MINFOUND MEDICAL SYSTEMS CO., LTD 197
- 19.17.1 COMPANY SNAPSHOT 197
- 19.17.2 PRODUCT PORTFOLIO 197
- 19.17.3 RECENT DEVELOPMENT 197

- 19.18 MYRIAD GENETICS, INC. 198
- 19.18.1 COMPANY SNAPSHOT 198
- 19.18.2 REVENUE ANALYSIS 198
- 19.18.3 PRODUCT PORTFOLIO 199
- 19.18.4 RECENT DEVELOPMENT 199
- 19.19 PLEXBIO 200
- 19.19.1 COMPANY SNAPSHOT 200
- 19.19.2 PRODUCT PORTFOLIO 200
- 19.19.3 RECENT DEVELOPMENT 200
- 19.20 QIAGEN 201
- 19.20.1 COMPANY SNAPSHOT 201
- 19.20.2 REVENUE ANALYSIS 201
- 19.20.3 PRODUCT PORTFOLIO 202
- 19.20.4 RECENT DEVELOPMENT 202
- 19.21 QUEST DIAGNOSTICS INCORPORATED 203
- 19.21.1 COMPANY SNAPSHOT 203
- 19.21.2 REVENUE ANALYSIS 203
- 19.21.3 PRODUCT PORTFOLIO 204
- 19.21.4 RECENT DEVELOPMENT 204
- 19.22 SIEMENS HEALTHCARE GMBH 205
- 19.22.1 COMPANY SNAPSHOT 205
- 19.22.2 REVENUE ANALYSIS 205
- 19.22.3 PRODUCT PORTFOLIO 206
- 19.22.4 RECENT DEVELOPMENT 206
- 19.23 STERNMED GMBH 207
- 19.23.1 COMPANY SNAPSHOT 207
- 19.23.2 PRODUCT PORTFOLIO 207
- 19.23.3 RECENT DEVELOPMENT 207
- 19.24 TIME MEDICAL HOLDING. 208
- 19.24.1 COMPANY SNAPSHOT 208
- 19.24.2 PRODUCT PORTFOLIO 208
- 19.24.3 RECENT DEVELOPMENT 208
- 20 OUESTIONNAIRE 209



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

NA Throat Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 213 pages | Data Bridge Market Research

select license	License			Price
	Single User License			\$3500.00
	Corporate Users License			\$4200.00
			VAT	
			Total	
lease circle the rele	vant license option. For any questions p	lease contact support@	scotts-international.com or 0048 603 3	94 346.
** VAT will be added	at 23% for Polish based companies, indi	ividuals and EU based c	companies who are unable to provide a	valid EU Va
		1		
mail*		Phone*		
irst Name*		Last Name*		
ob title*				
Company Name*		EU Vat / Tax ID / NIP number*		
		City*		
\ddress*				
		Country*		
		Country*	2025-05-06	
		_	2025-05-06	
Address* Zip Code*		_		

Scotts International. EU Vat number: PL 6772247784